Strides Pharma Science Ltd
NSE:STAR
Strides Pharma Science Ltd
Note Receivable
Strides Pharma Science Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Strides Pharma Science Ltd
NSE:STAR
|
Note Receivable
₹661.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Note Receivable
₹2.3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Note Receivable
₹3.3B
|
CAGR 3-Years
1 392%
|
CAGR 5-Years
45%
|
CAGR 10-Years
0%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Note Receivable
₹10.9B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-2%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Note Receivable
₹2.3B
|
CAGR 3-Years
87%
|
CAGR 5-Years
18%
|
CAGR 10-Years
7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Note Receivable
₹1.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Strides Pharma Science Ltd
Glance View
Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2000-02-03. The firm is focused on development and manufacture of IP-led niche and pharmaceutical products. The company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The firm manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as, liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. The company has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). The company is also engaged in manufacturing soft gelatin capsules. The company develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
See Also
What is Strides Pharma Science Ltd's Note Receivable?
Note Receivable
661.5m
INR
Based on the financial report for Dec 31, 2024, Strides Pharma Science Ltd's Note Receivable amounts to 661.5m INR.
What is Strides Pharma Science Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
-15%
Over the last year, the Note Receivable growth was -41%. The average annual Note Receivable growth rates for Strides Pharma Science Ltd have been -15% over the past three years , -15% over the past five years .
You don't have any saved screeners yet